Morgan Stanley Analyst Sees FY15 'Trough' For Johnson & Johnson Pharma Growth
January 22, 2015 at 11:54 AM EST
Johnson & Johnson (NYSE: JNJ) is entering a "trough year" for its all-important pharmaceuticals segment, an analyst ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.